[ad_1]
The first combination of tyrosine kinase inhibitor and immunotherapy is approved in Europe for adult patients with advanced or recurrent endometrial cancer, in any case the disease progresses before or after platinum-containing treatment and is not suitable for curative surgery or Radiotherapy
The approval based on the results of the 309/KEYNOTE-775 study proved that compared with chemotherapy, the overall survival rate and progression-free survival rate are statistically significantly improved
KENILWORTH, Tokyo and New Jersey, November 29, 2021-(JCN Newswire)-Eisai Co., Ltd. of Kenilworth, New Jersey, USA and Merck & Co. (known as MSD outside the US and Canada) today announced that the European Commission The oral multi-receptor tyrosine kinase inhibitor LENVIMA discovered by Eisai has been approved in combination with the anti-PD-1 therapy KEYTRUDA of Kenilworth Merck, New Jersey, United States for the treatment of advanced or recurrent endometrial cancer in adults. In any case, the disease progresses after receiving platinum-containing therapy treatment or treatment, and is not suitable for radical surgery or radiotherapy. This marks the first time that a combination of tyrosine kinase inhibitors and immunotherapy has been approved in Europe for these patients with advanced or recurrent endometrial cancer.
The approval is based on the results of the key Phase 3 study 309/KEYNOTE-775 trial, in which LENVIMA plus KEYTRUDA showed a statistically significant improvement in overall survival (OS), reducing…
The full story can be found on Benzinga.com
[ad_2]
Source link
